Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Signifor, Signifor LAR
Pasireotide, sold under the brand name Signifor, is a somatostatin analog used to treat Cushing's disease in patients who are not candidates for pituitary surgery or for whom surgery has failed. It acts by binding to somatostatin receptors, particularly subtype 5, which are overexpressed in certain neuroendocrine tumors. This binding inhibits the secretion of various hormones, including ACTH, which is responsible for the excessive cortisol production seen in Cushing's disease.
Used to treat Cushing's disease in patients who are not surgical candidates or for whom surgery has failed.
Outcome:
Increased risk of bradycardia
Mechanism:
Additive effects on heart rate
Outcome:
Additive bradycardic effects
Mechanism:
Synergistic effects on heart rate
Outcome:
Potential slight decrease in pasireotide absorption
Mechanism:
Chelation or altered gastric pH
Most likely new formulation: Oral sustained-release formulation (2026, 80% confidence)
Based on current usage trends and clinical trial results, there is a 70% likelihood of expanded indications for pasireotide in other neuroendocrine tumor types within the next 5 years.
Somatostatin Analog
Cyclohexapeptide